Similar articles

• New research and treatment options for acute myeloid leukemia.

  Miller CB. Miller CB. Am J Manag Care. 2000 Oct;6(18 Suppl):S973-4. Am J Manag Care. 2000. PMID: 11184567 No abstract available.
• Gemtuzumab for relapsed acute myeloid leukemia.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2000 Jul 24;42(1083):67-8. Med Lett Drugs Ther. 2000. PMID: 10908423 No abstract available.
• Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance.

  Radsak MP, Salih HR, Sökler M, Kanz L, Denzlinger C. Radsak MP, et al. Leukemia. 2002 Sep;16(9):1870-1. doi: 10.1038/sj.leu.2402594. Leukemia. 2002. PMID: 12200709 No abstract available.
• Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia.

  Williams JP, Handler HL. Williams JP, et al. Am J Manag Care. 2000 Oct;6(18 Suppl):S975-85. Am J Manag Care. 2000. PMID: 11184568 Review.
• Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.

  Frankel AE, Sievers EL, Scheinberg DA. Frankel AE, et al. Cancer Biother Radiopharm. 2000 Oct;15(5):459-76. doi: 10.1089/cbr.2000.15.459. Cancer Biother Radiopharm. 2000. PMID: 11155818 Review.